In case of various ACE inhibitors like enalapril, moexipril and perindopril the tendency of cyclization to the corresponding diketopiperazine impurity has been minimized by forming the acid or base addition salts. The techniques employed to stabilize other ACE inhibitors were found to be unsuccessful in case of quinapril. On storage specifically at elevated temperatures quinapril or its salts have been found to cyclize to DKP and also to diacid ('III' in fig. 1 ) through hydrolysis.
The product obtained by employing the process described in US Patent No. 4,344,949 for quinapril hydrochloride results in an amorphous solid. Guo et al. [8] describe stability and chemical degradation of amorphous quinapril hydrochloride. Due to the amorphous nature it gets readily converted to the diketopiperazine impurity at 80°. Studies on crystalline quinapril hydrochloride acetonitrile solvate shows that during heating of samples, initial evaporation of solvent at 60° occurs which is followed by cyclization to the diketopiperazine impurity by loss of water and hydrogen chloride.
Desolvation of stoicheometric solvates most of the times lead to a different crystal structure or results in a disordered or amorphous state [9] , with some exceptions [10] [11] [12] [13] . In case of quinapril hydrochloride solvates, the product gets totally converted to an amorphous solid on desolvation. On heating, solid quinapril hydrochloride gets converted to the diketopiperazine impurity, in the solid stage escape of hydrogen chloride is the rate limiting step, and in case of solution phase, formation of quinapril zwitterions is the rate limiting step, which can be accelerated by increasing the pH of the solution [14] . The schematic representation of various steps involved in formation of diketopiperazine impurity as described by Li et al [14] is provided in fig. 2 .
Some approaches to stabilize quinapril and/or quinapril hydrochloride are provided by Harris et al [15] , Sherman [16] , Klokkers et al [17, 18] , Li et al [14, 19] and Goel et al [20] . Although attempts to improve the stability of solid quinapril have been partially successful, no work has been reported for improvement of solution phase stability.
Intermolecular interactions between quinapril molecule and solvent molecule(s) would minimize the intramolecular interactions, which are responsible for formation of the diketopiperazine impurity. The crystalline structure formed in case of solvates would minimize the mobility of molecules which is more in case of amorphous solids [8] . This postulation lead to our earlier work [21] related to quinapril hydrochloride nitromethane solvate. Nitromethane solvate is comparatively more stable than other known solvates e.g. acetonitrile solvate, due to hydrogen bonding interaction between quinapril hydrochloride molecule and nitromethane. Apparently, acetonitrile solvate of quinapril hydrochloride shows inferior stability to that of nitromethane solvate because no hydrogen bonding has been observed in single crystal X-ray diffraction pattern in the former case.
In view of the above, attempts have been made to design a system wherein addition of a molecule could improve hydrogen bonding which in turn could impart stability to quinapril hydrochloride, preferably the free base. One such approach is to form a 'co-crystal' with a suitable molecule, which is generally recognized as safe to human beings (a GRAS molecule).
The term 'co-crystal' [22] [23] [24] [25] [26] [27] [28] [29] represents a long known class of compounds, a prototypal is quinhydrone and is broadly defined as "a mixed crystal of crystals that contains two different molecules". Supramolecular chemistry and crystal engineering concept defines it as a consequence of a molecular recognition event between different molecular species. Basically cocrystals are made from reactants that are solids at ambient temperature; this fact distinguishes solvates/ hydrates from co-crystals. In solvates, at least one component should be a liquid at ambient temperature; in hydrates, it is water [22] .
MATERIALS AND METHODS
All solvents used for experiments were of HPLC grade. Tris(hydroxymethyl)amino methane and tertbutylamine were purchased from M/S S. D. Fine Chemicals Ltd., Mumbai, India. 1 H NMR spectra were recorded on a Bruker 400MHz spectrometer, powder X-ray diffraction was recorded on PANalytical B.V., Netherlands model PN3040/60X'Part Pro., FT IR spectra were recorded on a Perkin-Elmer model spectrum 100, thermal analyses were done on a Mettler Toledo DSC 821e. The solvates of quinapril hydrochloride with acetonitrile [20] , acetone [30] , toluene [31] and methyl formate [30] were prepared by the process reported in literature. The method as published by Singh et al [21] was utilized to prepare the nitromethane solvate. Quinapril magnesium salt and quinapril hydrochloride were prepared according to the process reported by Sharman [16] and Hoefle [5] respectively. 
Preparation
,4-tetrahydro-3-isoquinoline carboxylic acid benzyl ester maleate salt (quinapril benzyl ester maleate salt) 25 g (0.0388 mol) was dissolved in a mixture of 125 ml water and 125 ml dichloromethane. The pH of the solution was adjusted between 7.5 and 8.5 by addition of aqueous ammonia. Reaction mixture was stirred for 30 min, the organic phase separated and washed with 50 ml water. The organic phase was evaporated under reduced pressure below 40°, the free base of quinapril benzyl ester was obtained.
The above obtained residue of quinapril benzyl ester was dissolved in 140 ml ethanol to which 1.0 g of 10% Pd/C and 6.0 g of 35% hydrochloric acid were added. The reaction mass was subjected to catalytic hydrogenation at 40-60 psi pressure and 20-30°. The reaction mass was filtered and the filtrate evaporated to give crude quinapril hydrochloride.
The residue obtained was dissolved in nitromethane (125 ml) and the solvent recovered below 35° under reduced pressure. This operation was repeated till the water content of the residue was less than 0.5%. Nitromethane (125 ml) was added to the above residue of quinapril hydrochloride and the mixture was stirred at 20-25° for 10-15 min to get a clear solution. The mixture was stirred at the same temperature for 30 min and seeded with pure quinapril hydrochloride. The mass was cooled to 5-10° and stirred at the same temperature for 2 h. The reaction mass was then filtered and the wet cake was washed with nitromethane (50 ml), to give crystalline quinapril hydrochloride nitromethane solvate. 
Preparation of (S,S,S)2-{2-[(1-ethoxycarbonyl-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid tris(hydroxymethyl)amino methane salt:
Quinapril benzyl ester maleate salt 25 g (0.0388 mol) was converted to quinapril benzyl ester as per the procedure provided above. The residue of quinapril benzyl ester was dissolved in 250 ml ethanol. Palladium on charcoal (10%), 2.5 g, tris(hydroxymethyl)amino methane 4.7 g (0.0388 mol) and 60 ml water were added to the ethanol solution. The reaction mass was subjected to catalytic hydrogenation at 40-60 psi pressure at 20-30° for 2 h. After completion of reaction, the reaction mass was filtered and the filtrate was evaporated to dryness. To the residue, 100 ml acetonitrile was added and stirred for 30 min. The solid was filtered and dried at 40-45° for 10 h to give 22 g quinapril tris(hydroxymethyl) amino methane salt.
FTIR Spectra (KBr, cm -1 ): Please refer to 
Preparation of (S,S,S)2-{2-[(1-ethoxycarbonyl-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid tertiary butyl amine salt [quinapril erbumine salt]:
Quinapril benzyl ester maleate salt 25 g (0.0388 mol) was converted to quinapril benzyl ester as per the procedure provided above. The residue of quinapril benzyl ester was dissolved in 250 ml ethanol. To this solution, 2.5 g of 10% Pd/C and 4.25 g (0.0582 mol) tertiary butyl amine were added. The reaction mass was subjected to catalytic hydrogenation at 40-60 psi pressure at 20-30° for 2 h. After completion of reaction, the reaction mass was filtered at 50° and the filtrate evaporated to dryness. To the residue, 100 ml acetonitrile was added and stirred for 30 min. The solid was filtered and dried at 40-45° for 10 h. Dry weight of quinapril tertiary butyl amine salt: 20 g FTIR Spectra (KBr, cm -1 ) were presented in HPLC conditions set for analysis of samples: HPLC analysis was performed using Shimazdu instrument, mobile phase used was Ammonium phosphate buffer+methane sulfonic acid [pH=4] and column used was Zorbax SB-CN, 4.6×250 mm. The detector wavelength was set to 210 nm. Throughout the analysis the flow rate was set to 1.5 ml per minute. Each sample (concentration 2000 ppm) was run for 60 min and the column oven temperature was set to 40° during analysis.
Other analytical methods and description of instruments:
NMR spectra were obtained on a 400 MHz Bruker instrument, with CDCl 3 /DMSO-d 6 as solvent. Chemical shifts (δ) are given in ppm relative to tetramethylsilane (δ = 0 ppm) or to residual protons in the solvent as internal standard. IR spectra were recorded with a PerkinElmer Spectrometer (Spectrum 100), and absorption bands are given in cm -1 . TGA were recorded on PerkinElmer model Pyris 1 at the heating rate of 10 °/min and weight loss is given in percentage. DSC was recorded on Perkin Elmer model Diamond DSC at the heating rate of 10 °/min and endothermic peak is reported in ° and ∆H is reported in J/g. Melting point was recorded on Mettler Toledo apparatus with 1 °/min heating rate. Moisture content was determined by Karl Fischer titration method with a Metrohm instrument. Measurement of specific optical rotation was done on a Jasco, Model No. P1030 at the wavelength of 589 nm.
Thermal stability studies:
Quinapril hydrochloride solvates (10 g each) of nitromethane, acetone, toluene, acetonitrile, methyl formate, dry quinapril hydrochloride, quinapril tris, quinapril hydrochloride, quinapril erbumine, quinapril magnesium salt(s)were kept at 60° and 80° in different drying ovens for 48 h. Samples of each were withdrawn after every 4 h for analysis of DKP impurity. Rates of degradation of quinapril to DKP were calculated by regression analysis, wherein coefficient of correlation was more than 98%. The ratio of rate of degradation of individual salt with that of dry quinapril hydrochloride was calculated (Table 2) .
Solution Phase stability study:
For solution phase stability study quinapril hydrochloride/quinapril tris salt(s) (100 mg each) were dissolved in 1 ml each of water, 0.1N hydrochloride solution, 4.5 phosphate buffer solution, 6.8 phosphate buffer solution, 7.5 phosphate buffer solution in separate sample vials and kept for 30 min at 25°. Then each sample was analyzed by HPLC to detect impurity level. The results are provided in Table 3 .
Single crystal X Ray Diffraction Analysis:
Single crystal of nitromethane solvate of quinapril hydrochloride was obtained by dissolving quinapril hydrochloride in nitromethane and allowing it to crystallize. Suitable crystal of quinapril tris was selected from the bulk for X-ray diffraction analysis. The crystallographic data and details of data collection of the compounds, viz. quinapril hydrochloride nitromethane solvate and quinapril tris, are given in Tables 4 and 5 , respectively. Crystal of suitable size was selected and immersed in partone oil, then mounted on the tip of a glass fiber and cemented using epoxy resin. Intensity data for the compound was collected using MoK α (λ = 0.71073Å) radiation on a Bruker Smart Apex diffractometer equipped with CCD area detector at 100K. The data integration and reduction was processed with SAINT [32] software. An empirical absorption correction was applied to the collected reflections using SADABS [33] program . The structure was solved by direct methods using SHELXTL [34] and was refined on F 2 by the full-matrix least-squares technique using the SHELXL-97 [35] program package. All non-hydrogen atoms except ethyl carbon atoms of the ethyl acetate moiety (which are disordered) were refined anisotropically till convergence was reached. The occupancy factor for the disordered ethyl group was calculated by the FVAR command of the SHELXTL program and the disordered atoms were refined only isotropically. The hydrogen atoms of these disordered atoms were not included in the final refinement cycles. Hydrogen atoms attached to the ligand moieties were stereochemically fixed. The diagrams of the crystal structures were generated using the programs ORTEP5 [36] , Mercury 1.4.1 [37] and PALTON [38] . and toluene (110°) are closer, nitromethane solvate was found to be three times more stable than that of toluene solvate at 60°. To understand this phenomenon the powder and single crystal X-ray diffraction of the solvates of quinapril hydrochloride were studied. Powder X-ray diffraction pattern of all the solvates were found to be almost similar to each other, hence it is likely that the crystal systems of all these solvates would be similar.
RESULTS AND DISCUSSION
ORTEP diagram of the quinapril nitromethane solvate is depicted in fig. 4c . Details of crystallographic data are summarized in Table 4 . 171°) with the ketonic oxygen O3. In addition to the above interactions, weak intramolecular C-H…O contact exist between (i) ketonic oxygen O3 and the H12 attached to the asymmetric carbon and (ii) the acetate oxygen O4 with the H11 of the heterocyclic ring. Details of all these pertinent hydrogen-bonding interactions, along with symmetry code, are given in Table 6 .
Hence, it is evident from the crystal structure analysis the hydrogen bonding interactions between nitromethane and quinapril hydrochloride molecule provide comparatively more stability to the product. However, such interactions are weak, if present, in case of acetonitrile solvate [39, 40] , and probably may not be present in the other known quinapril hydrochloride solvates as evident from their stability data.
Thermo gravimetric analysis of quinapril tris salt shows no weight loss. Differential scanning calorimetric analysis shows single endothermic peak at 156°, unlike quinapril hydrochloride showing first peak at 166° of degradation and a second peak corresponding to the melting point of the diacid impurity (III) of quinapril [8] .
In FTIR spectrum (Table 1) , the -OH stretching vibration (3709 cm -1 ) of carboxylic function in quinapril is seen in quinapril erbumine salt but absent in quinapril tris salt. Further, it can also be noted that the carbonyl stretching vibrations seen at the wavelengths of 1647 and 1648 cm -1 in quinapril erbumine salt and quinapril hydrochloride salt respectively are shifted to 1625 cm -1 in case of quinapril tris salt. Shifting of carbonyl stretch and absence of -OH stretch of carbonyl function of quinapril in quinapril tris salt is attributed to involvement of these groups in intermolecular hydrogen bonding.
An ORTEP [37] view of asymmetric unit of quinapril tris salt with atom numbering scheme is shown in fig. 5 . The conformation of the quinapril molecule is established by the torsion angles N1-C12-C13-N2 150.3(5)˚, N2-C16-C17-C18 -62.5(6)˚ and C16-C17-C18-C19 -167.8(5)˚. The hetero ring (C1/N1/C3/C4/ C9/C10) assumes a screw-boat conformation with ring puckering parameters [41] Q=0.551(5) Å, θ=69.7(6)˚ and φ=-27.9(6)˚, respectively. The molecular structure of the title compound is stabilized by several intermolecular hydrogen bonds (Table 7) It is evident from the single crystal X-ray diffraction and FTIR data, the interactions between quinapril and tris(hydroxymethyl)amino methane occurs by two phenomena viz. (a) formation of amine salt (b) complex intermolecular hydrogen bonding network. Hence, it imparts stability not only by the ionic bond but also through hydrogen bonds similar to co-crystal formation, which was not possible in quinapril erbumine and quinapril hydrochloride salts as evident from comparison of thermal stabilities of the quinapril tris salt and quinapril erbumine salt (Table 2) Impurity levels in quinapril tris surprisingly remains unchanged at 80° even up to 72 h, however impurity levels in quinapril hydrochloride, quinapril erbumine and quinapril magnesium increased significantly. Rate of formation of DKP impurity in quinapril tris salt is the lowest (Table 2) .
Solution phase stability study of these salts reveals significant increase in concentration of DKP and diacid impurity at different pH in case of quinapril hydrochloride after 30 min at 25°, however there is no significant change in the impurity level in case of quinapril tris salt (Table 3) . Solubility study of quinapril tris salt and quinapril hydrochloride in water, ethanol and methanol at 20° reveals that quinapril tris salt has comparable solubility as that of quinapril hydrochloride (Table 8 ).
The single crystal X-ray diffraction analysis of acetonitrile solvate of quinapril hydrochloride [39, 40] does not show hydrogen-bonding interaction between the solvent molecule and the host. The solvent molecule just fit into the cavities of the crystal lattice to impart stability. On the other hand, nitromethane solvate of quinapril hydrochloride is comparatively more stable among all the other solvates due to strong hydrogen bonding interaction between nitromethane molecule and quinapril molecule, thereby imparting superior stability.
In quinapril tris salt, quinapril is not only bound with tris(hydroxymethyl)amino methane by the way of ionic bond, but also bound with a complex hydrogen bonding network involving large number of hydrogen bond donors and acceptors. This formation of complex hydrogen bonding network imparts solid-state stability as evident from comparison of thermal stabilities quinapril tris salt and quinapril erbumine salt, as tert-butylamine does not contain large number of hydrogen bond donors like that of tris (hydroxymethyl)amino methane. The interactions between quinapril and tris(hydroxymethyl)amino methane occurs by two phenomena viz. (a) formation of amine salt (b) complex intermolecular hydrogen bonding network. Hence, it imparts stability not only by the ionic bond but also through hydrogen bonds similar to co-crystal formation, which was not possible in quinapril erbumine and quinapril hydrochloride salts.
Quinapril tris salt would be a potential alternative to be formulated as a drug product to the existing solvates and salt forms of quinapril in view of its stability and comparable solubility to that of quinapril hydrochloride.
